{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:44:42Z","timestamp":1787237082023,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["CYYY-YJSJGXM-202409"],"award-info":[{"award-number":["CYYY-YJSJGXM-202409"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijcard.2025.133952","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:02:22Z","timestamp":1759460542000},"page":"133952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative efficacy of particulate embolic agents versus alcohol in percutaneous transluminal septal myocardial ablation"],"prefix":"10.1016","volume":"443","author":[{"given":"Yunshu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yintao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2024","key":"10.1016\/j.ijcard.2025.133952_bb0005","first-page":"e1239","article-title":"AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2025.133952_bb0010","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/0735-1097(93)90196-8","article-title":"An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy","volume":"22","author":"Sherrid","year":"1993","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2025.133952_bb0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"30","key":"10.1016\/j.ijcard.2025.133952_bb0020","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"Hypertrophic cardiomyopathy outcomes investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"O'Mahony","year":"2014","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.ijcard.2025.133952_bb0025","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1053\/euhj.1999.2019","article-title":"Percutaneous transluminal septal myocardial ablation: a new treatment for hypertrophic obstructive cardiomyopathy","volume":"21","author":"Seggewiss","year":"2000","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2025.133952_bb0030","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.111.076257","article-title":"Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy","volume":"126","author":"Sorajja","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2025.133952_bb0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.107.738740","article-title":"Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy","volume":"118","author":"Sorajja","year":"2008","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ijcard.2025.133952_bb0040","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jacc.2006.08.055","article-title":"Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy","volume":"49","author":"Valeti","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"41","key":"10.1016\/j.ijcard.2025.133952_bb0045","first-page":"2849","article-title":"The 2014 ESC guidelines on the diagnosis and Management of Hypertrophic Cardiomyopathy have been published","volume":"35","author":"Nicholls","year":"2014","journal-title":"Eur. Heart J."},{"issue":"8969","key":"10.1016\/j.ijcard.2025.133952_bb0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0140-6736(95)91267-3","article-title":"Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy","volume":"346","author":"Sigwart","year":"1995","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ijcard.2025.133952_bb0055","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/eurheartj\/ehv693","article-title":"Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the euro-ASA registry","volume":"37","author":"Veselka","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2025.133952_bb0060","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2021.02.056","article-title":"Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy","volume":"333","author":"Veselka","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2025.133952_bb0065","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1136\/hrt.2006.092007","article-title":"Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy","volume":"92","author":"Baggish","year":"2006","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.ijcard.2025.133952_bb0070","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1161\/CIRCULATIONAHA.104.508309","article-title":"Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets","volume":"112","author":"van der Lee","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ijcard.2025.133952_bb0075","doi-asserted-by":"crossref","first-page":"369","DOI":"10.21037\/acs.2017.05.09","article-title":"Alcohol septal ablation: in which patients and why?","volume":"6","author":"Spirito","year":"2017","journal-title":"Ann. Cardiothorac. Surg."},{"issue":"7","key":"10.1016\/j.ijcard.2025.133952_bb0080","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1157\/13077240","volume":"58","author":"Antolinos P\u00e9rez","year":"2005","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.ijcard.2025.133952_bb0085","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s11604-014-0292-2","article-title":"Guidelines on the use of gelatin sponge particles in embolotherapy","volume":"32","author":"Miyayama","year":"2014","journal-title":"Jpn. J. Radiol."},{"key":"10.1016\/j.ijcard.2025.133952_bb0090","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/00000658-194611000-00010","article-title":"Studies on the use of gelatin sponge or foam as an hemostatic agent in experimental liver resections and injuries to large veins","volume":"124","author":"Jenkins","year":"1946","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ijcard.2025.133952_bb0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3171\/jns.1967.27.4.0315","article-title":"Treatment of carotid-cavernous fistula by gelfoam embolization","volume":"27","author":"Ishimori","year":"1967","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ijcard.2025.133952_bb0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.tvir.2008.03.002","article-title":"Gelatine sponge particles: handling characteristics for endovascular use","volume":"10","author":"Abada","year":"2007","journal-title":"Tech. Vasc. Interv. Radiol."},{"key":"10.1016\/j.ijcard.2025.133952_bb0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s002709900108","article-title":"Dependency of tissue necrosis on gelatin sponge particle size after canine hepatic artery embolization","volume":"20","author":"Sonomura","year":"1997","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.ijcard.2025.133952_bb0110","first-page":"231","article-title":"Percutaneous septal ablation with absorbable gelatin sponge in hypertrophic obstructive cardiomyopathy","volume":"69","author":"Llamas-Esper\u00f3n","year":"2007","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"3","key":"10.1016\/j.ijcard.2025.133952_bb0115","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2214\/ajr.175.3.1750767","article-title":"Embolic agents used for uterine fibroid embolization","volume":"175","author":"Siskin","year":"2000","journal-title":"AJR Am. J. Roentgenol."},{"issue":"6","key":"10.1016\/j.ijcard.2025.133952_bb0120","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1583\/03-1171MR.1","article-title":"Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 3-year outcomes","volume":"11","author":"Gross","year":"2004","journal-title":"J. Endovasc. Ther."},{"issue":"24","key":"10.1016\/j.ijcard.2025.133952_bb0125","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1016\/j.jacc.2018.09.064","article-title":"Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy","volume":"72","author":"Batzner","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.ijcard.2025.133952_bb0130","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.amjcard.2005.12.040","article-title":"Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy","volume":"97","author":"Yoerger","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2025.133952_bb0135","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2025.133952_bb0140","unstructured":"I. Olivotto, A. Oreziak, R. Barriales-Villa, et al., Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet 396 (2020) 759\u2013769. doi:https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X. (Erratum in: Lancet 396 (2020) 758. doi:https:\/\/doi.org\/10.1016\/S0140-6736(20)31872-9)."},{"key":"10.1016\/j.ijcard.2025.133952_bb0145","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00392-007-0579-8","article-title":"Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy","volume":"96","author":"Seggewiss","year":"2007","journal-title":"Clin. Res. Cardiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325009957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325009957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:34:33Z","timestamp":1778672073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527325009957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"alternative-id":["S0167527325009957"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133952","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of particulate embolic agents versus alcohol in percutaneous transluminal septal myocardial ablation","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"133952"}}